Question 1

What is DaVita's P/FCF ratio?

Accepted Answer

DaVita (DVA) P/FCF ratio is 10.7× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month free cash flow, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/FCF ratio calculated?

Accepted Answer

P/FCF = Market Capitalisation ÷ Trailing Twelve-Month (TTM) Free Cash Flow, where Free Cash Flow = Operating Cash Flow − Capital Expenditures. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/FCF ratio?

Accepted Answer

The price-to-free-cash-flow (P/FCF) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) free cash flow. It is calculated as market cap ÷ TTM free cash flow, where free cash flow = operating cash flow − capital expenditures. Because FCF cannot be inflated by non-cash accounting items, P/FCF is often considered a cleaner measure of "earnings-power valuation" than P/E — especially for capital-intensive businesses where depreciation diverges from real cash outflows.

Question 4

What is a good P/FCF ratio for DaVita?

Accepted Answer

Mature companies that consistently convert profit into cash often trade at 15–25× P/FCF; capital-intensive businesses with lumpy capex typically trade lower. Compare against sector peers and against the company's own multi-year average — single-year P/FCF can be distorted by working-capital swings. For DaVita specifically, the relevant sector benchmark is the current sector median of 19.1×.

Question 5

Is DaVita's P/FCF ratio high or low?

Accepted Answer

DaVita's P/FCF ratio of 10.7× is above its own 5-year average of 8.2× and below the sector median of 19.1×. That places the current reading at the 85th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is DaVita's historical P/FCF ratio range?

Accepted Answer

In the available daily series, DaVita (DVA) P/FCF ratio has ranged from a low of 5.0× in 2023 to a high of 39.4× in 2015. The 5-year average is 8.2× and the 5-year median is 7.4×.

Question 7

What was DaVita's P/FCF ratio in 2025?

Accepted Answer

DaVita (DVA) P/FCF ratio at the end of 2025 was 7.5×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month free cash flow figure available at that date.

Question 8

Why does DaVita's P/FCF ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (free cash flow). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$9.78B	$1.31B	7.5×	-0.9×	Dec 31, 2025
2024	$12.2B	$1.47B	8.3×	+2.0×	Dec 31, 2024
2023	$9.47B	$1.49B	6.3×	-0.7×	Dec 31, 2023
2022	$6.73B	$961M	7.0×	-1.9×	Dec 31, 2022
2021	$11.5B	$1.29B	8.9×	-1.1×	Dec 31, 2021
2020	$13.1B	$1.3B	10.1×	+2.6×	Dec 31, 2020
2019	$9.71B	$1.31B	7.4×	-3.5×	Dec 31, 2019
2018	$8.54B	$785M	10.9×	-2.3×	Dec 31, 2018
2017	$13.2B	$1B	13.1×	+2.2×	Dec 31, 2017
2016	$12.5B	$1.13B	11.0×	-6.2×	Dec 31, 2016
2015	$14.6B	$849M	17.1×	-2.6×	Dec 31, 2015
2014	$16.1B	$817M	19.7×	+8.2×	Dec 31, 2014
2013	$13.3B	$1.15B	11.6×	-8.7×	Dec 31, 2013
2012	$11.2B	$551M	20.3×	+11.2×	Dec 31, 2012
2011	$7.09B	$780M	9.1×	-2.7×	Dec 31, 2011
2010	$6.69B	$566M	11.8×	-3.6×	Dec 31, 2010
2009	$6.03B	$392M	15.4×	-6.2×	Dec 31, 2009
2008	$5.15B	$238M	21.6×	-1.7×	Dec 31, 2008
2007	$6.02B	$259M	23.3×	-0.3×	Dec 31, 2007
2006	$5.93B	$251M	23.6×	+7.7×	Dec 31, 2006
2005	$5.16B	$324M	15.9×	+2.6×	Dec 31, 2005
2004	$3.87B	$292M	13.3×	+0.3×	Dec 31, 2004
2003	$2.51B	$193M	13.0×	+6.8×	Dec 31, 2003
2002	$1.48B	$239M	6.2×	—	Dec 31, 2002


Align Technology (ALGN)	17.8×
McKesson (MCK)	17.8×
Gilead Sciences (GILD)	16.9×
DexCom (DXCM)	16.9×
Pfizer (PFE)	16.7×
Humana (HUM)	16.4×
Quest Diagnostics (DGX)	16.3×
UnitedHealth Group (UNH)	15.9×
Labcorp Holdings (LH)	15.9×
Becton, Dickinson and (BDX)	14.0×
HCA Healthcare (HCA)	13.5×
Elevance Health (ELV)	13.4×
Incyte (INCY)	12.9×
CVS Health (CVS)	12.4×
Universal Health Services (UHS)	12.2×
Baxter International (BAX)	12.1×
Cardinal Health (CAH)	11.3×
IQVIA (IQV)	11.3×
Bristol-Myers Squibb (BMY)	10.4×
Biogen (BIIB)	10.3×
Zimmer Biomet Holdings (ZBH)	9.6×
Cigna (CI)	9.1×
Viatris (VTRS)	9.1×
Teladoc Health (TDOC)	3.9×
Centene (CNC)	2.5×

P/FCF Ratio for DaVita (DVA) 2002-2026

P/FCF Ratio daily chart for DaVita (DVA)

Historical P/FCF Ratio for DaVita (DVA) from 2002 to 2025

About P/FCF Ratio at DaVita (DVA)

DaVita P/FCF Ratio by Year

DaVita P/FCF Ratio 2025: 7.5×

DaVita P/FCF Ratio 2024: 8.3×

DaVita P/FCF Ratio 2023: 6.3×

DaVita P/FCF Ratio 2022: 7.0×

DaVita P/FCF Ratio 2021: 8.9×

Sector peers by P/FCF Ratio — chart

Sector peers by P/FCF Ratio — table

Frequently asked questions

DaVita (DVA) Key Financials